#AI4S# is back in focus. $MRNA's historic Phase 3 cancer vaccine win reignited interest in how AI and data could reshape biotech. In Hong Kong, #DiagensTech# (HKEX: 2526) is gaining attention. H1 revenue rose 21% YoY, while model-service revenue jumped 101%, now accounting for 87% of total revenue. Other AI4S names in focus include #InsilicoMedicine# (HKEX: 3696) and #XtalPi# (HKEX: 2228). All are tradable on StableStock. → Not investment advice. For informational purposes only.